Efficacy of a live bovine herpesvirus type 1 marker vaccine under field conditions in three countries
- B. Makoschey, DrMedVet1,
- H-H. Zehle, DrMedVet2,
- M. Bussacchini, DVM3,
- G. Valla, DVM3,
- V. Pálfi, DVM, PhD4 and
- J. Földi, DVM5
- 1 International Marketing Department, Intervet International, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands
- 2 Landesamt für Verbraucherschutz Sachsen-Anhalt, Fachbereich 4, Veterinäruntersuchungen und Veterinärepidemiologie, Haferbreiter Weg 132-135, 39576 Stendal, Germany
- 3 Intervet Italia, Via Walter Tobagi 7, 20068 Peschiera Borromeo (MI), Italy
- 4 Department of Virology, Országos Állategészségügyi Intézet, National Veterinary Institute of Budapest, Tábornok u 2, 1149 Budapest, Hungary
- 5 Intervet Hungaria, Boráros tér 7/II. 7.e.13, 1905 Budapest, Hungary
Abstract
The performance of a live marker vaccine for bovine herpesvirus type 1 (bhv-1) was studied in the field in three European Union countries with different farming conditions. The progress in the eradication of the virus was followed in a large herd in Germany and one in Italy, and a major serological survey involving 147 farms was conducted in Hungary. Commercial batches of the same vaccine were used in all three studies. The herds were vaccinated according to agreed protocols and the animals' bhv-1 antibody status was determined at local institutes by using commercial glycoprotein B (gB)- and glycoprotein E (gE)-elisas. In all three studies, the seroprevalence of bhv-1 gE decreased progressively. Given the starting conditions and the long duration of the studies, reactivation events and virus circulation would have been more likely to have occurred if the herds had not been vaccinated.
- British Veterinary Association. All rights reserved.
